An automated nucleic acid amplification test widely used for early detection of tuberculosis in countries where the disease is more prevalent also worked well in the United States, suggesting the ...

Cepheid announced it has received clearance from the Food and Drug Administration (FDA) to market Xpert Norovirus, an in vitro diagnostic test for identification and differentiation of Noroviruses ...

SUNNYVALE, Calif., May 29, 2019 /PRNewswire/ -- Cepheid announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for testing throat and rectal specimens with its ...

In the policy statement on the Xpert MTB/RIF test in 2011, the WHO recommended the use of the test as an initial diagnostic tool among children with suspected HIV associated TB or MDR TB based on ...

Cepheid has announced the European release of the Xpert™ MRSA (Methicillin-resistant Staphylococcus aureus) test for clinical diagnostic use on the GeneXpert ® System. The MRSA test was released as a ...

Cepheid just received CE-IVD mark for its Xpert TV molecular test for identifying Trichomoniasis infections in both men and women. The test will run on Cepheid's GeneXpert System, the world’s leading ...

Please provide your email address to receive an email when new articles are posted on . The manufacturer of Xpert Norovirus, the first on-demand molecular test for detection of norovirus, has received ...

Viral load assay will be made available at concessionary prices to public and non-for-profit providers. FIND (Foundation for Innovative New Diagnostics) has agreed to put $5 million into a ...

In an attempt to strengthen its foothold in the virology market, molecular diagnostics corporation Cepheid ( CPHD), together with the not-for-profit organization - Foundation for Innovative New ...